Elizabeth M Kang

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Chronic granulomatous disease: overview and hematopoietic stem cell transplantation
    Elizabeth M Kang
    Laboratory of Host Defenses, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Allergy Clin Immunol 127:1319-26; quiz 1327-8. 2011
  2. pmc Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils
    Elizabeth M Kang
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Blood 115:783-91. 2010
  3. doi request reprint Advances in treatment for chronic granulomatous disease
    Elizabeth M Kang
    National Institutes of Health, Building 10 Room 6 3752, 10 Center Drive, Bethesda, Maryland 20892, USA
    Immunol Res 43:77-84. 2009
  4. ncbi request reprint Gene therapy-based treatment for HIV-positive patients with malignancies
    Elizabeth M Kang
    Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA
    J Hematother Stem Cell Res 11:809-16. 2002
  5. pmc Allogeneic hematopoietic stem-cell transplantation for sickle cell disease
    Matthew M Hsieh
    Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA
    N Engl J Med 361:2309-17. 2009
  6. pmc Long-term vector integration site analysis following retroviral mediated gene transfer to hematopoietic stem cells for the treatment of HIV infection
    Jun Hayakawa
    National Institutes of Diabetes and Digestive and Kidney Disorders NIDDK and National Heart, Lung, and Blood Institute NHLBI, National Institutes of Health NIH, Bethesda, Maryland, USA
    PLoS ONE 4:e4211. 2009
  7. pmc Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population
    Sumithira Vasu
    Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 112:2092-100. 2008
  8. pmc Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model
    Elizabeth M Kang
    Laboratory of Host Defense, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA
    Exp Hematol 34:132-9. 2006
  9. doi request reprint Gene therapy for chronic granulomatous disease
    Elizabeth M Kang
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Methods Enzymol 507:125-54. 2012
  10. ncbi request reprint Cloning and functional analysis of the rhesus macaque ABCG2 gene. Forced expression confers an SP phenotype among hematopoietic stem cell progeny in vivo
    Takahiro Ueda
    Molecular and Clinical Hematology Branch, NIDDK, National Instiutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 280:991-8. 2005

Detail Information

Publications24

  1. pmc Chronic granulomatous disease: overview and hematopoietic stem cell transplantation
    Elizabeth M Kang
    Laboratory of Host Defenses, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Allergy Clin Immunol 127:1319-26; quiz 1327-8. 2011
    ..We will then discuss the status of bone marrow transplantation...
  2. pmc Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils
    Elizabeth M Kang
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Blood 115:783-91. 2010
    ..This study was registered at www.clinicaltrials.gov as #NCT00394316...
  3. doi request reprint Advances in treatment for chronic granulomatous disease
    Elizabeth M Kang
    National Institutes of Health, Building 10 Room 6 3752, 10 Center Drive, Bethesda, Maryland 20892, USA
    Immunol Res 43:77-84. 2009
    ..Additionally, gene therapy, which has been a long touted method to cure CGD, has within the last 5-10 years become more and more of a reality and may be realized by the end of this decade...
  4. ncbi request reprint Gene therapy-based treatment for HIV-positive patients with malignancies
    Elizabeth M Kang
    Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA
    J Hematother Stem Cell Res 11:809-16. 2002
    ..Vector-transduced cells remain detectable at low levels more than 3 years post-transplantation, suggesting the potential for gene therapy as a reasonable goal for the treatment of HIV...
  5. pmc Allogeneic hematopoietic stem-cell transplantation for sickle cell disease
    Matthew M Hsieh
    Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA
    N Engl J Med 361:2309-17. 2009
    ..Graft rejection and graft-versus-host disease (GVHD) are additional barriers to its success. We performed nonmyeloablative stem-cell transplantation in adults with sickle cell disease...
  6. pmc Long-term vector integration site analysis following retroviral mediated gene transfer to hematopoietic stem cells for the treatment of HIV infection
    Jun Hayakawa
    National Institutes of Diabetes and Digestive and Kidney Disorders NIDDK and National Heart, Lung, and Blood Institute NHLBI, National Institutes of Health NIH, Bethesda, Maryland, USA
    PLoS ONE 4:e4211. 2009
    ..Interestingly, an integration site near the MDS1 gene was detected in long-term follow-up samples; however, the overall contribution of MDS1 integrated clone remained stably low during follow-up...
  7. pmc Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population
    Sumithira Vasu
    Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 112:2092-100. 2008
    ..Age, white ethnicity, and female gender were associated with significantly lower post-G-CSF CD34(+) cell counts...
  8. pmc Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model
    Elizabeth M Kang
    Laboratory of Host Defense, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA
    Exp Hematol 34:132-9. 2006
    ..To decrease the toxicity profile, we sought to develop nonmyeloablative conditioning regimens and in this work, explored the use of intravenous busulfan in a large animal model...
  9. doi request reprint Gene therapy for chronic granulomatous disease
    Elizabeth M Kang
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Methods Enzymol 507:125-54. 2012
    ..We are also exploring novel alternate approaches to gene therapy using zinc finger nuclease-mediated gene targeting of induced pluripotent stem cells derived from CGD patients...
  10. ncbi request reprint Cloning and functional analysis of the rhesus macaque ABCG2 gene. Forced expression confers an SP phenotype among hematopoietic stem cell progeny in vivo
    Takahiro Ueda
    Molecular and Clinical Hematology Branch, NIDDK, National Instiutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 280:991-8. 2005
    ....
  11. pmc Primary Immune Deficiency Treatment Consortium (PIDTC) report
    Linda M Griffith
    Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md Electronic address
    J Allergy Clin Immunol 133:335-47. 2014
    ..Here we report the progress of the PIDTC to date, highlights of the first 2 PIDTC workshops, and consideration of future consortium objectives. ..
  12. ncbi request reprint The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications
    Elizabeth M Kang
    Molecular and Clinical Hematology Branch, National Institutes of Diabetes and Digestive and Kidney Disorders, National Institutes of Health, Building 10, Room 9N116, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Curr Hematol Rep 3:274-81. 2004
    ..In this review, we describe this complication, discuss the leukemogenic risk of integrating retroviral vectors, and propose strategies to decrease the likelihood of its occurrence...
  13. pmc Low-dose parenteral busulfan provides an extended window for the infusion of hematopoietic stem cells in murine hosts
    Matthew M Hsieh
    Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Exp Hematol 35:1415-20. 2007
    ..As an alternative to TBI, escalating doses of parenteral busulfan were tested for their hematologic toxicity, their ability to promote donor leukocyte engraftment, and the time window for such engraftment...
  14. pmc Hypomorphic Rag mutations can cause destructive midline granulomatous disease
    Suk See De Ravin
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 116:1263-71. 2010
    ..This study was registered at www.clinicaltrials.gov as #NCT00128973...
  15. ncbi request reprint Eosinophils from lineage-ablated Delta dblGATA bone marrow progenitors: the dblGATA enhancer in the promoter of GATA-1 is not essential for differentiation ex vivo
    Kimberly D Dyer
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases National Institutes of Health NIAID NIH, Bethesda, MD 20892, USA
    J Immunol 179:1693-9. 2007
    ....
  16. ncbi request reprint Hematopoietic stem cell transplantation prevents diabetes in NOD mice but does not contribute to significant islet cell regeneration once disease is established
    Elizabeth M Kang
    LHD NIAID, National Institutes of Health DHHS, Bethesda, MD 20895, USA
    Exp Hematol 33:699-705. 2005
    ....
  17. ncbi request reprint Low-dose radiation plus rapamycin promotes long-term bone marrow chimerism
    Jonathan D Powell
    Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA
    Transplantation 80:1541-5. 2005
    ..Although a number of regimens have been explored, the optimal means of conditioning has not been determined...
  18. ncbi request reprint Retrovirally transduced muscle-derived cells contribute to hematopoiesis at very low levels in the nonhuman primate model
    Chunji Gao
    Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Disorders, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Ther 8:974-80. 2003
    ..These results demonstrate that harvesting disparate organs for cellular therapy is currently highly inefficient at best...
  19. pmc Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease
    Suk See De Ravin
    Laboratory of Host Defense, National Institutes of Allergy and Infectious Diseases, Bethesda, MD, USA
    Clin Infect Dis 52:e136-43. 2011
    ....
  20. pmc Adenosine A₂A receptor agonist-mediated increase in donor-derived regulatory T cells suppresses development of graft-versus-host disease
    Kyu Lee Han
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 190:458-68. 2013
    ..Furthermore, the increased presence of Tregs in target tissues (colon and skin) of A(2A)R-specific agonist-treated mice is likely the mechanistic basis for the anti-inflammatory effect preventing acute GVHD...
  21. ncbi request reprint Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait
    Elizabeth M Kang
    Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Disorders, National Institutes of Health, 9000 Rockville Pike, Bldg 10, Bethesda, MD 20892, USA
    Blood 99:850-5. 2002
    ..001). The study concluded that filgrastim mobilization, large volume apheresis, processing, and cryopreservation appears to be safe in donors with SCT, allowing PBSC use for transplantation in patients with sickle cell anemia...
  22. ncbi request reprint Sarcoidosis in chronic granulomatous disease
    Suk See De Ravin
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Pediatrics 117:e590-5. 2006
    ..Serum angiotensin-converting enzyme levels were measured in 26 other patients with CGD to establish an appropriate reference range. A possible relationship between CGD and sarcoidosis is discussed...
  23. pmc Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management
    Linda M Griffith
    Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Allergy Clin Immunol 124:1152-60.e12. 2009
    ..Finally, we discuss the role of high-quality databases in treatment of PIDs and HCT as an element of the infrastructure that will be needed for productive multicenter clinical trials in these rare diseases...
  24. ncbi request reprint Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome
    Elizabeth M Kang
    Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 99:698-701. 2002
    ..These results suggest that nonmyeloablative allogeneic transplantation in the context of highly active antiretroviral therapy is feasible in patients with treatment-sensitive HIV infection...